X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (315) 315
multiple sclerosis (213) 213
index medicus (202) 202
clinical neurology (177) 177
interferon beta-1a (172) 172
female (152) 152
adult (149) 149
male (147) 147
multiple sclerosis - drug therapy (146) 146
injections, intramuscular (142) 142
double-blind (139) 139
interferon-beta - therapeutic use (116) 116
placebo-controlled trial (115) 115
interferon-beta - administration & dosage (114) 114
glatiramer acetate (112) 112
intramuscular interferon beta-1a (110) 110
multiple sclerosis, relapsing-remitting - drug therapy (108) 108
middle aged (100) 100
intramuscular interferon (97) 97
treatment outcome (97) 97
magnetic resonance imaging (84) 84
neurosciences (74) 74
adjuvants, immunologic - administration & dosage (63) 63
disease progression (61) 61
neurology (61) 61
pharmacology & pharmacy (58) 58
immunosuppressive agents - therapeutic use (56) 56
interferon-beta - adverse effects (55) 55
interferon (50) 50
oral fingolimod (50) 50
adolescent (48) 48
adjuvants, immunologic - therapeutic use (47) 47
disability (46) 46
follow-up (44) 44
immunologic factors - therapeutic use (43) 43
interferon beta-1b (43) 43
injections, subcutaneous (42) 42
multicenter (41) 41
interferon beta (40) 40
medicine, general & internal (40) 40
therapy (40) 40
brain - pathology (39) 39
drug therapy (39) 39
disability evaluation (38) 38
fingolimod (38) 38
multiple sclerosis - diagnosis (38) 38
time factors (38) 38
young adult (37) 37
clinically isolated syndromes (36) 36
natalizumab (36) 36
care and treatment (35) 35
double-blind method (34) 34
multiple sclerosis - pathology (34) 34
clinical trials (33) 33
peptides - therapeutic use (33) 33
efficacy (31) 31
magnetic-resonance (31) 31
progressive multifocal leukoencephalopathy (31) 31
follow-up studies (30) 30
recurrence (30) 30
drug administration schedule (29) 29
interferon-beta (29) 29
immunosuppressive agents - adverse effects (27) 27
diagnostic-criteria (26) 26
fingolimod hydrochloride (26) 26
mri (26) 26
natural-history (26) 26
sphingosine - analogs & derivatives (26) 26
disease-activity (25) 25
retrospective studies (25) 25
adjuvants, immunologic - adverse effects (24) 24
disease-modifying therapy (24) 24
immunosuppressive agents - administration & dosage (24) 24
multiple sclerosis - therapy (24) 24
neutralizing antibodies (24) 24
1st demyelinating event (23) 23
clinical trials as topic (23) 23
clinically isolated syndrome (23) 23
disease (23) 23
patients (22) 22
biological response modifiers (21) 21
controlled phase-3 trial (21) 21
medicine & public health (21) 21
multiple sclerosis - physiopathology (21) 21
multiple sclerosis, relapsing-remitting - pathology (21) 21
oral teriflunomide (21) 21
propylene glycols - therapeutic use (21) 21
prospective studies (21) 21
randomized controlled trials as topic (21) 21
sphingosine - therapeutic use (21) 21
brain atrophy (20) 20
cohort studies (20) 20
multiple sclerosis - immunology (20) 20
multiple-sclerosis (20) 20
quality-of-life (20) 20
research (20) 20
safety (20) 20
trial (20) 20
abridged index medicus (19) 19
administration, oral (19) 19
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (340) 340
French (7) 7
German (7) 7
Russian (4) 4
Spanish (3) 3
Hungarian (2) 2
Japanese (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 6/2012, Volume 52, Issue 6, pp. 798 - 808
This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple... 
polyethylene glycol | pharmacokinetics and drug metabolism | multiple sclerosis | pharmacodynamics | biomarkers | NEUTRALIZING ANTIBODIES | EFFICACY | ADHERENCE | DELIVERY | NEED | THERAPY | PHARMACOLOGY & PHARMACY | COMPARATIVE PHARMACOKINETICS | 2',5'-Oligoadenylate Synthetase - blood | Humans | Middle Aged | Interferons - adverse effects | Half-Life | Polyethylene Glycols - adverse effects | Male | RNA, Messenger - metabolism | Dose-Response Relationship, Drug | T-Lymphocytes, Helper-Inducer - drug effects | Young Adult | Immunosuppressive Agents - blood | Interferon-beta - adverse effects | Interferons - blood | Biotransformation | Injections, Subcutaneous | Adult | Female | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Polyethylene Glycols - pharmacology | 2',5'-Oligoadenylate Synthetase - metabolism | Interferon-beta - administration & dosage | Interferon-beta - chemistry | T-Lymphocytes, Helper-Inducer - metabolism | Double-Blind Method | Interferons - pharmacology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Injections, Intramuscular | Neopterin - blood | Polyethylene Glycols - administration & dosage | 2',5'-Oligoadenylate Synthetase - genetics | Gene Expression Regulation - drug effects | Interferons - administration & dosage | RNA, Messenger - blood | Interferon-beta - pharmacology | Adolescent | Immunosuppressive Agents - adverse effects | Usage | Pharmacology | Health aspects | Sclerosis | Multiple sclerosis | Pharmacodynamics | Helper cells | Data processing | Leukocytes (neutrophilic) | Lymphocytes T | Gene expression | neopterin | Lymphocytes | alpha -Interferon | Interferon | Pharmacokinetics
Journal Article
NEUROLOGY, ISSN 0028-3878, 10/2016, Volume 87, Issue 14, pp. 1464 - 1472
Objective: To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I... 
RELAPSING MULTIPLE-SCLEROSIS | BRAIN ATROPHY | SURROGATE | ORAL FINGOLIMOD | INTRAMUSCULAR INTERFERON | METAANALYTIC APPROACH | END-POINTS | CONTROLLED PHASE-3 TRIAL | LESIONS | CLINICAL NEUROLOGY | DISEASE PROGRESSION
Journal Article
Multiple Sclerosis, ISSN 1352-4585, 08/2009, Volume 15, Issue 8, pp. 965 - 976
Background Studies evaluating interferon beta (IFNβ) for multiple sclerosis (MS) showed only partial efficacy. In many patients, IFNβ does not halt relapses or... 
Disease modifying therapies | Corticosteroids | Azathioprine | Beta-interferon | Placebo-controlled | BRAIN ATROPHY | EFFICACY | MRI | GUIDELINES | beta-interferon | azathioprine | METHYLPREDNISOLONE | CLINICAL NEUROLOGY | THERAPY | corticosteroids | DISEASE | DOUBLE-BLIND | placebo-controlled | PLACEBO-CONTROLLED TRIAL | disease modifying therapies | RELAPSING-REMITTING MS | Recurrence | Azathioprine - administration & dosage | Prospective Studies | Humans | Multiple Sclerosis, Relapsing-Remitting - diagnosis | Atrophy | Time Factors | Interferon-beta - adverse effects | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Disability Evaluation | Interferon-beta - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Immunologic Factors - administration & dosage | Treatment Outcome | Injections, Intramuscular | Disease Progression | Adrenal Cortex Hormones - adverse effects | Magnetic Resonance Imaging | Interferon beta-1a | Brain - pathology | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Azathioprine - adverse effects | Adrenal Cortex Hormones - administration & dosage | Index Medicus
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 11/2017, Volume 23, Issue 13, pp. 1736 - 1747
Background: No evidence of disease activity (NEDA) is a composite endpoint being increasingly applied as an outcome measure in clinical trials as well as... 
treatment | Composite outcome | magnetic resonance imaging | no evidence of disease activity | clinical endpoints | disease-activity-free | radiological endpoints | daclizumab | relapsing-remitting multiple sclerosis | AXONAL DAMAGE | IMMUNOSUPPRESSIVE TREATMENT | CLINICAL-COURSE | NEUROSCIENCES | CLINICAL NEUROLOGY | MYELIN BASIC-PROTEIN | FLUID | FIBRILLARY ACIDIC PROTEIN | DISABILITY | NEUROFILAMENT LIGHT | OPTIC NEURITIS | Outcome Assessment (Health Care) - methods | Adjuvants, Immunologic - administration & dosage | Adjuvants, Immunologic - pharmacology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Multiple Sclerosis, Relapsing-Remitting - physiopathology | Injections, Intramuscular | Immunoglobulin G - administration & dosage | Interferon beta-1a - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacology | Injections, Subcutaneous | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Interferon beta-1a - pharmacology | Immunoglobulin G - pharmacology | Adult | Female | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Multiple sclerosis | Nuclear magnetic resonance--NMR | Magnetic resonance imaging | Clinical trials | Gadolinium | Interferon | Regression analysis
Journal Article
Neurology, ISSN 0028-3878, 06/2009, Volume 72, Issue 23, pp. 1989 - 1993
Journal Article